Bleakley Financial Group LLC Invests $563,000 in Aquestive Therapeutics, Inc. $AQST

Bleakley Financial Group LLC bought a new position in Aquestive Therapeutics, Inc. (NASDAQ:AQST) during the first quarter, Holdings Channel reports. The firm bought 135,767 shares of the company’s stock, valued at approximately $563,000.

Other large investors have also added to or reduced their stakes in the company. NewEdge Advisors LLC acquired a new position in Aquestive Therapeutics during the 3rd quarter valued at about $28,000. BNP Paribas Financial Markets increased its holdings in Aquestive Therapeutics by 78.3% during the 2nd quarter. BNP Paribas Financial Markets now owns 9,413 shares of the company’s stock worth $31,000 after purchasing an additional 4,134 shares in the last quarter. Lineweaver Wealth Advisors LLC purchased a new stake in shares of Aquestive Therapeutics in the fourth quarter worth approximately $65,000. Modern Wealth Management LLC purchased a new stake in shares of Aquestive Therapeutics in the second quarter worth approximately $33,000. Finally, Elevation Point Wealth Partners LLC purchased a new stake in shares of Aquestive Therapeutics in the first quarter worth approximately $42,000. Institutional investors own 32.45% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently issued reports on AQST. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aquestive Therapeutics in a research report on Monday, April 20th. Oppenheimer started coverage on Aquestive Therapeutics in a report on Friday, April 24th. They set an “outperform” rating and a $8.00 price target for the company. Finally, Wall Street Zen raised Aquestive Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Aquestive Therapeutics currently has an average rating of “Buy” and a consensus target price of $8.50.

Aquestive Therapeutics Price Performance

AQST opened at $4.12 on Friday. Aquestive Therapeutics, Inc. has a fifty-two week low of $2.93 and a fifty-two week high of $7.55. The firm has a market capitalization of $516.94 million, a P/E ratio of -6.75 and a beta of 1.45. The company’s 50-day moving average is $4.22 and its 200 day moving average is $4.19.

Aquestive Therapeutics (NASDAQ:AQST) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.07. The firm had revenue of $14.45 million during the quarter, compared to the consensus estimate of $10.90 million. On average, equities research analysts expect that Aquestive Therapeutics, Inc. will post -0.41 earnings per share for the current year.

Insider Activity at Aquestive Therapeutics

In other news, Director Julie Krop sold 25,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 23rd. The stock was sold at an average price of $5.02, for a total value of $125,500.00. Following the transaction, the director owned 25,000 shares in the company, valued at $125,500. The trade was a 50.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Barber sold 8,257 shares of the company’s stock in a transaction that occurred on Friday, May 15th. The shares were sold at an average price of $4.29, for a total value of $35,422.53. Following the completion of the transaction, the chief executive officer directly owned 660,574 shares of the company’s stock, valued at approximately $2,833,862.46. This represents a 1.23% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.81% of the stock is owned by company insiders.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.